logo
Plus   Neg
Share
Email

Greenlight Financial Raises $260 Mln, Valuation Nearly Doubles To $2.3 Bln

Fintech company Greenlight Financial Technology, Inc. on Tuesday said that it has raised $260 million in Series D funding.

The series was initiated by Andreessen Horowitz with active support from return investors TTV Capital, Canapi Ventures, Wells Fargo Strategic Capital, BOND, Fin VC, Goodwater Capital, as well as new investors like Wellington Management, Owl Ventures and LionTree Partners.

With this investment, the company's total funding has reached more than $550 million and its valuation has risen from $1.2 billion to $2.3 billion in the last six months.

Greenlight Financial plans to use the funding to speed up product development in order to add more financial features to its portfolio. The funding will also be used for setting up facilities across different places and to invest more in strategic distribution firms.

Greenlight also plans to hire 300 more employees in order to improve its engineering services over the coming two years.

Commenting on the funding, Tim Sheehan, co-founder and CEO, Greenlight, said, "Today's financing will enable us to bring even more value to families as we continue to introduce new innovative products that shine a light on the world of money."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Fashion retailer L Brands, Inc. announced Tuesday that its Board of Directors has unanimously approved a plan to separate the company into two independent publicly traded companies. The two public companies will be Bath & Body Works, one of the world's leading bath, body and home fragrance retailers, and Victoria's Secret, including Victoria's Secret Lingerie, PINK and Victoria's Secret Beauty. Danish pharmaceutical company Novo Nordisk A/S is recalling 1,468 product samples of Levemir, Tresiba, Fiasp, Novolog and Xultophy to the consumer level, due to improper storage temperature conditions, the U.S. Food and Drug Administration said. The Food and Drug Administration on Monday expanded the emergency use authorization of Pfizer-BioNTech's Covid-19 vaccine to include 12- to 15-year-olds. "The FDA's expansion of the emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine to include adolescents 12 through 15 years of age...
Follow RTT